Temporally Constrained Group Sparse Learning for Longitudinal Data Analysis in Alzheimer's Disease
IEEE Transactions on Bio-Medical Engineering
|April 20, 2016
Summary
This study introduces a new sparse learning method for analyzing brain images over time to improve Alzheimer's disease diagnosis. The novel approach enhances disease progression pattern discovery and biomarker identification using longitudinal data.
Area of Science:
- Neuroimaging
- Machine Learning
- Biomedical Data Analysis
Background:
- Sparse learning is used for Alzheimer's disease (AD) and mild cognitive impairment (MCI) diagnosis using brain imaging.
- Existing methods often rely on cross-sectional data, limiting the analysis of disease progression.
- Longitudinal data offers potential for deeper insights into neurodegenerative disease patterns.
Purpose of the Study:
- To propose a novel temporally-constrained group sparse learning method for longitudinal brain image analysis.
- To leverage multiple time-points of data for improved disease progression pattern uncovering.
- To enhance the diagnostic capabilities for Alzheimer's disease and mild cognitive impairment.
Main Methods:
- Developed a temporally-constrained group sparse learning model for longitudinal data.
- Incorporated group regularization to link brain region weights across time-points.
- Introduced fused and output smoothness regularization terms to model temporal changes.
- Designed an efficient optimization algorithm for the proposed model.
Main Results:
- The proposed method achieved improved regression performance compared to conventional sparse learning techniques.
- Demonstrated effectiveness in identifying disease-related biomarkers from longitudinal brain imaging data.
- Experimental validation conducted on the Alzheimer's Disease Neuroimaging Initiative (ADNI) database.
Conclusions:
- The novel temporally-constrained group sparse learning method effectively analyzes longitudinal brain imaging data.
- The approach enhances the understanding of disease progression patterns in Alzheimer's disease.
- The method shows promise for improved diagnosis and biomarker discovery in neurodegenerative diseases.
More Related Videos
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
2.0K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
8.5K
Related Concept Videos
Longitudinal Research
13.6K
Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.6K
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Longitudinal Studies
649
Longitudinal studies are also widely used in other medical and social science fields. For instance, in cardiovascular research, they can monitor patients' health over decades to identify risk factors for heart disease, such as high cholesterol or smoking, and evaluate the long-term effectiveness of preventive measures. Similarly, in mental health studies, researchers might follow individuals from adolescence into adulthood to understand the development and progression of conditions like...
649
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
